Circulating miR-21, miR-29a, and miR-126 are associated with premature death risk due to cancer and cardiovascular disease: the JACC Study.
Adult
Aged
Biomarkers, Tumor
/ blood
Case-Control Studies
Circulating MicroRNA
/ blood
Coronary Artery Disease
/ blood
Early Detection of Cancer
/ methods
Female
Follow-Up Studies
Humans
Japan
/ epidemiology
Male
MicroRNAs
/ blood
Middle Aged
Mortality, Premature
Neoplasms
/ blood
Real-Time Polymerase Chain Reaction
/ methods
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 03 2021
05 03 2021
Historique:
received:
14
04
2020
accepted:
19
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
21
12
2021
Statut:
epublish
Résumé
Primary prevention of premature death is a public health concern worldwide. Circulating microRNAs (miRNAs) have been described as potential diagnostic biomarkers for diseases as cancer and cardiovascular disease (CVD). This case-cohort study aimed to investigate the potential relationship between circulating miRNAs and the risk of premature death. A total of 39,242 subjects provided baseline serum samples in 1988-1990. Of these, 345 subjects who died of intrinsic disease (< 65 years old) and for which measurable samples were available were included in this study. We randomly selected a sub-cohort of 879 subjects. Circulatring miR-21, miR-29a, and miR-126 were determined using qRT-PCR. Conditional logistic regression models were used to analyse the data with respect to stratified miRNA levels. Multivariable logistic regression revealed that subjects with high circulating miR-21 and miR-29a individual levels had a significantly higher risk of total death, cancer death, and CVD death than those with medium miR-21 and miR-29a individual levels. Conversely, subjects with low circulating miR-126 levels had a significantly higher risk of total death than those with medium levels. This suggests that circulating miRNAs are associated with the risk of premature death from cancer and CVD, identifying them as potential biomarkers for early detection of high-risk individuals.
Identifiants
pubmed: 33674633
doi: 10.1038/s41598-021-84707-7
pii: 10.1038/s41598-021-84707-7
pmc: PMC7935984
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating MicroRNA
0
MIRN126 microRNA, human
0
MIRN21 microRNA, human
0
MIRN29a microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5298Références
J Epidemiol. 2013;23(3):227-32
pubmed: 23583921
Circulation. 2015 Oct 27;132(17):1667-78
pubmed: 26503749
Clin Chem. 2015 Sep;61(9):1138-55
pubmed: 26319452
J Epidemiol. 2020 Apr 5;30(4):177-182
pubmed: 30905898
Ann Oncol. 2017 May 1;28(5):1124-1129
pubmed: 28453699
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1516-21
pubmed: 18227515
EBioMedicine. 2016 Oct;12:68-71
pubmed: 27614396
Diabetes. 2017 Feb;66(2):347-357
pubmed: 27899485
Clin Cancer Res. 2015 Sep 15;21(18):4234-42
pubmed: 26038573
Sci Rep. 2014 May 22;4:5026
pubmed: 24848278
Nat Commun. 2018 Jul 2;9(1):2560
pubmed: 29967491
J Epidemiol. 2004 Nov;14(6):177-81
pubmed: 15617390
Heart Int. 2016 Apr 26;11(1):e1-e9
pubmed: 27924211
JAMA. 2014 Jan 8;311(2):164-71
pubmed: 24399555
Lancet. 2014 Apr 26;383(9927):1465-1473
pubmed: 24486187
J Mol Cell Cardiol. 2015 Dec;89(Pt B):122-35
pubmed: 25655936
J Cell Physiol. 2019 Nov;234(11):19280-19297
pubmed: 30950056
Lancet Oncol. 2015 Jul;16(7):804-15
pubmed: 26088272
Clin Chim Acta. 2013 Sep 23;424:99-103
pubmed: 23727030
Clin Endocrinol (Oxf). 2014 Aug;81(2):276-81
pubmed: 24533739
J Epidemiol. 2005 Jul;15(4):107-12
pubmed: 16141628
Front Immunol. 2015 Jan 29;6:19
pubmed: 25688245
J Epidemiol Community Health. 2015 Mar;69(3):207-17; discussion 205-6
pubmed: 24964740
Sci Rep. 2017 Jan 16;7:40363
pubmed: 28091607
Sci Rep. 2019 Dec 11;9(1):18856
pubmed: 31827150
Circ Res. 2012 Feb 3;110(3):483-95
pubmed: 22302755
Sci Rep. 2018 Dec 19;8(1):17981
pubmed: 30568292
J Epidemiol. 2014;24(5):370-8
pubmed: 24857957
Thyroid. 2016 Oct;26(10):1431-1440
pubmed: 27610819
Cancer Biomark. 2015;15(1):47-56
pubmed: 25524942
Mol Ther Nucleic Acids. 2018 Sep 7;12:146-157
pubmed: 30195754
Ann Clin Biochem. 2018 Jul;55(4):437-445
pubmed: 28920467
Lancet. 2017 Mar 25;389(10075):1229-1237
pubmed: 28159391
Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):11-24
pubmed: 29141851
Biochem Biophys Res Commun. 2015 Jul 17-24;463(1-2):60-3
pubmed: 25986735
Epigenetics. 2014 Jan;9(1):129-41
pubmed: 24149370
BMC Public Health. 2015 Nov 25;15:1177
pubmed: 26607570
Cancer Biomark. 2012;12(4):199-204
pubmed: 23568010
Neurol Sci. 2018 Oct;39(10):1757-1765
pubmed: 30030634
J Am Coll Cardiol. 2005 Nov 1;46(9):1761-7
pubmed: 16256882
J Am Coll Cardiol. 2012 Jul 24;60(4):290-9
pubmed: 22813605
Molecules. 2015 Oct 20;20(10):19030-40
pubmed: 26492230
Drug Dev Res. 2015 Sep;76(6):270-7
pubmed: 26082192
Dis Markers. 2015;2015:435656
pubmed: 26063956
Am J Epidemiol. 2005 Jan 15;161(2):170-9
pubmed: 15632267
Clin Chim Acta. 2015 Jun 15;446:267-71
pubmed: 25958847
Circ Res. 2010 Sep 17;107(6):810-7
pubmed: 20651284
BMC Med. 2016 Jun 14;14:87
pubmed: 27296932
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281
J Am Heart Assoc. 2014 Oct 27;3(6):e001249
pubmed: 25349183
Lancet. 2014 Jul 5;384(9937):45-52
pubmed: 24996589
BMC Nephrol. 2019 Dec 21;20(1):474
pubmed: 31864304
Clin Res Hepatol Gastroenterol. 2017 Mar;41(2):181-189
pubmed: 27839726
Lancet. 2017 Mar 11;389(10073):1043-1054
pubmed: 28131493
Sci Rep. 2017 Nov 10;7(1):15277
pubmed: 29127370
Cancer Epidemiol. 2010 Jun;34(3):279-84
pubmed: 20427254
Eur J Cancer. 2007 Jul;43(10):1611-6
pubmed: 17532620